Literature DB >> 17410012

Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial.

Riichiroh Maruyama1, Hideki Yokoyama, Takashi Seto, Seiji Nagashima, Kosuke Kashiwabara, Jun Araki, Hiroshi Semba, Yukito Ichinose.   

Abstract

INTRODUCTION: Malignant pericardial effusion (MPE) causes cardiac tamponade and an extremely poor outcome unless it is well controlled. The effect of pericardial drainage and the intra-pericardial instillation of bleomycin on the control of MPE was examined in this prospective multi-institutional phase II trial.
METHODS: In eligible patients with cytologically defined MPE resulting from non-small cell lung cancer, the pericardial effusion of such cases was continuously drained. After complete drainage, 10 mg of bleomycin was then locally instilled via a catheter. The catheter was then removed if the total amount of drainage was less than 30 ml/day. If the catheter could not be removed within 5 days after treatment, bleomycin was administered one more time.
RESULTS: Among the 22 patients who entered this trial, the tube drainage catheter was successfully removed from 17 patients with one instillation, whereas four required such instillation twice and one required such instillation three times. No severe adverse events were observed, except for constrictive pericarditis, which resulted in the treatment-related death of one patient. The control rate of pericardial effusion was 95% +/- 0.09 (95% confidence interval). No restoration of pericardial effusion was observed during the follow-up period or until death from any cause. Median survival time from the beginning of the protocol was 17.9 weeks.
CONCLUSIONS: Pericardial drainage followed by the instillation of bleomycin was found to be a safe and effective method for the management of MPE associated with non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410012     DOI: 10.1097/JTO.0b013e31802c8260

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  5 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  Pericarditis and pericardial effusion: management update.

Authors:  Dina M Sparano; R Parker Ward
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

3.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

4.  Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy.

Authors:  Bob T Li; Antonia Pearson; Nick Pavlakis; David Bell; Adrian Lee; David Chan; Michael Harden; Manu Mathur; David Marshman; Peter Brady; Stephen Clarke
Journal:  J Clin Med       Date:  2014-12-30       Impact factor: 4.241

5.  Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.

Authors:  Hisao Imai; Kyoichi Kaira; Ken Masubuchi; Koichi Minato
Journal:  Curr Oncol       Date:  2021-12-30       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.